Shopping Cart 0
Cart Subtotal
USD 0

Redx Pharma Plc (REDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Redx Pharma Plc (Redx Pharma), formerly Redx Pharma Ltd is a drug discovery and development company that develops early stage and small molecule therapeutics. The company's pipeline products include inhibitors for oncology and anti-infectives for treatment of diseases that include influenza and hepatitis B. Its proprietary redox switch is employed to generate novel antiviral and antibacterial drugs in the region of infectious disease. Redx Pharma's redox switch is also used for delivering multiple development candidates over mechanistic approaches in the treatment of cancer. The company conducts research through its facilities in the UK. Redx Pharma is headquartered in Macclesfield, the UK.

Redx Pharma Plc (REDX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Redx Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Redx Pharma Acquires ROCK Inhibitor AMA0825 from Amakem 11

Partnerships 12

Horizon Discovery Enters into Research Agreement with Redx Pharma 12

Astrazeneca Enters into Research Agreement with Redx Pharma 13

Redx Pharma Enters into Research Agreement with Pierre Fabre Labs 14

Licensing Agreements 15

Deinove Enters into Option and Licensing Agreement with Redx Pharma 15

Redx Pharma Enters Into Licensing Agreement With Pharmascience For Cancer Program 16

Dotmatics Enters Into Licensing Agreement With Redx Pharma 17

Redx Pharma Enters Into Licensing Agreement With Dishman For Prescription Drug Technology 18

Equity Offering 19

Redx Pharma to Raise USD15 Million in Private Placement of Shares 19

Redx Pharma to Raise USD3.6 Million in Rights Offering of Shares 21

Redx Pharma Raises USD14.2 Million in Private Placement of Shares 22

Redx Pharma Raises USD22.7 Million in IPO 23

Asset Transactions 24

Loxo Oncology Acquires BTK Inhibitor Program from Redx Pharma 24

Redx Pharma Plc-Key Competitors 25

Redx Pharma Plc-Key Employees 26

Redx Pharma Plc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 28

Financial Announcements 28

May 30, 2018: Redx Pharma: Interim results for the six months ended 31 March 2018 28

Dec 20, 2017: Redx Pharma: Final Results for the Year Ended 30 September 2017 31

May 17, 2017: Redx Pharma: Interim Results for the six months ended 31 March 2017 33

Mar 21, 2017: Redx Pharma Announces Final results for the year ended 30 September 2016 34

Corporate Communications 35

Jun 04, 2018: REDX PHARMA: Directorate Update 35

Jun 04, 2018: Redx Pharma Appoints Lisa Anson As Chief Executive Officer 36

Aug 14, 2017: Redx announces the resignation of Non-Executive Director David Lawrence 37

Apr 20, 2017: Redx Pharma: Appointment of Chairman 38

Legal and Regulatory 39

Oct 27, 2017: Redx Pharma: Update on Application to the High Court 39

Government and Public Interest 40

Mar 30, 2017: Redx Pharma awarded USD 1 million grant by CARB-X 40

Product News 41

08/31/2017: Redx to present new scientific data at ESMO 2017 41

06/23/2017: Redx announces MHRA approval of its Clinical Trial Application for Porcupine Inhibitor RXC004 42

01/27/2017: Redx outlines growing opportunity for Porcupine inhibitors 43

01/22/2018: Redx Pharma Announces Appointment of Experienced Drug Development Clinician as Chief Medical Officer 44

Clinical Trials 45

Jan 22, 2018: Redx Pharma appoints chief medical officer who will oversee launch of phase I clinical trial of new cancer drug 45

Other Significant Developments 46

Nov 06, 2017: Redx Provides a Strategic Update and Announces that Trading is to recommence in its Shares 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Redx Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Redx Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Redx Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Redx Pharma Acquires ROCK Inhibitor AMA0825 from Amakem 11

Horizon Discovery Enters into Research Agreement with Redx Pharma 12

Astrazeneca Enters into Research Agreement with Redx Pharma 13

Redx Pharma Enters into Research Agreement with Pierre Fabre Labs 14

Deinove Enters into Option and Licensing Agreement with Redx Pharma 15

Redx Pharma Enters Into Licensing Agreement With Pharmascience For Cancer Program 16

Dotmatics Enters Into Licensing Agreement With Redx Pharma 17

Redx Pharma Enters Into Licensing Agreement With Dishman For Prescription Drug Technology 18

Redx Pharma to Raise USD15 Million in Private Placement of Shares 19

Redx Pharma to Raise USD3.6 Million in Rights Offering of Shares 21

Redx Pharma Raises USD14.2 Million in Private Placement of Shares 22

Redx Pharma Raises USD22.7 Million in IPO 23

Loxo Oncology Acquires BTK Inhibitor Program from Redx Pharma 24

Redx Pharma Plc, Key Competitors 25

Redx Pharma Plc, Key Employees 26

Redx Pharma Plc, Subsidiaries 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Redx Pharma Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.